uniQure N.V. (QURE): Capital Expenditures
$439.0K
Year ended 2025-12-31
$453.0K
Trailing 12 months to 2026-03-31
-70.8%
3-year compound annual growth
-43.0%
5-year compound annual growth
-24.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $439.0K | -87.0% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $3.37M | -52.9% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $7.15M | -59.6% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $17.69M | +1.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $17.44M | +139.8% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $7.27M | +28.7% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $5.65M | +137.0% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $2.38M | -46.6% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $4.46M | -70.8% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $15.29M | +101.0% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $7.61M | -65.7% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $22.20M | n/a | 2017-03-15, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | $439.0K | -87.0% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | -100.0% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $9.0K | -96.2% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $109.0K | +505.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $47.0K | n/m |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $51.3K | n/a |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $3.37M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | $235.0K | +167.0% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $5.0K | -64.3% |
Compare QURE, ABUS, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗